Overview

Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy

Status:
Active, not recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
To quantify rates of bleeding events and investigate the characteristics of prescribed patients, rates of bleeding events, persistence and healthcare resource utilization of Oral Anticoagulants (OACs) prescribed in routine clinical practice.
Phase:
N/A
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Pfizer
Treatments:
Apixaban
Dabigatran
Rivaroxaban